Ilkka L.
- Country
- Finland
- Department
- Comprehensive Cancer Center
Research Overview
- Phase 2 Study of Pembrolizumab, MK-1084, and Combination Therapy in Patients With Advanced or Metastatic KRAS G12C-Mutant Nonsquamous Non-Small Cell Lung Cancer
- A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase 3 Randomized Study of PF-08046054/SGN-PDL1V vs. Docetaxel in PD-L1 Positive Non-Small Cell Lung Cancer Patients
Data & Insights
Has run more than one trial at 15 of 139 partner sites.
Specializations
Hematologic malignancies
Clinical research activity centers on acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, and relapsed or refractory lymphoma, with additional involvement in multiple myeloma and chronic lymphocytic leukemia.
- Relapsed/refractory leukemia
- Non-Hodgkin lymphoma
- Multiple myeloma
Therapeutic interest extends across novel immunotherapies, targeted combinations, and transplant-related strategies in blood cancers.
Solid tumors and genitourinary oncology
The investigator is involved in studies of prostate cancer, renal cell carcinoma, breast cancer, melanoma, and colorectal cancer, including advanced and metastatic disease settings.
- Metastatic prostate cancer
- Renal cell carcinoma
- Melanoma
These activities include interest in immuno-oncology, targeted therapy, and treatment optimization for high-risk solid tumors.
Neurology and cerebrovascular disease
Research engagement includes acute ischemic stroke, high-risk transient ischemic attack, refractory status epilepticus, and other epileptic encephalopathies.
- Stroke prevention
- Seizure disorders
- Neurological emergencies
Therapeutic focus also covers antithrombotic approaches and acute neurovascular intervention.
Cardiovascular and renal medicine
The clinical portfolio includes atrial fibrillation, heart failure, coronary artery disease, chronic kidney disease, and kidney transplant rejection.
- Thromboembolic prevention
- Heart failure
- Renal transplantation
There is also involvement in bleeding-risk management and renal-cardiovascular comorbidity.
Pediatric and rare disease therapeutics
Additional research spans pediatric leukemia, achondroplasia, Ewing sarcoma, medulloblastoma, and selected rare genetic disorders.
- Pediatric oncology
- Growth disorders
- Rare disease treatment
Therapeutic interests also include inherited bleeding disorders and other uncommon conditions requiring specialized clinical development.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.